Rise of PD-L1 expression during metastasis of colorectal cancer: Implications for immunotherapy

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · see citing works

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · see citing works

Colorectal cancer statistics, 2017

Siegel, R. L., Miller, K. D., Fedewa, S. A., Ahnen, D. J., Meester, R. G. S., Barzi, A., & Jemal, A. (2017) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21395 · Cited by 3,807 · see citing works

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · see citing works

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324 · see citing works

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

Li, C., Lim, S., Xia, W., Lee, H., Chan, L.-C., Kuo, C., Khoo, K., Chang, S.-S., Cha, J., Kim, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms12632 · Cited by 1,100 · see citing works

Diet, microorganisms and their metabolites, and colon cancer

O'Keefe, S. J. D. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.165 · Cited by 1,100 · see citing works

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

Hugo, W., Shi, H., Sun, L., Piva, M., Song, C., Kong, X., Moriceau, G., Hong, A., Dahlman, K. B., Johnson, D. B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.061 · Cited by 596 · see citing works

Therapy-induced tumour secretomes promote resistance and tumour progression

Obenauf, A. C., Zou, Y., Ji, A. L., Vanharanta, S., Shu, W., Shi, H., Kong, X., Bosenberg, M., Wiesner, T., Rosen, N. X., et al. (2015) · Nature · doi:10.1038/nature14336 · Cited by 485 · see citing works

Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma

Callea, M., Albiges, L. K., Gupta, M., Cheng, S., Genega, E. M., Fay, A. P., Song, J., Carvo, I., Bhatt, R. S., Atkins, M. B., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0043 · Cited by 459 · see citing works

PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes

Rosenbaum, M. W., Bledsoe, J. R., Morales‐Oyarvide, V., Huynh, T. G., & Mino-Kenudson, M. A. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.95 · Cited by 289 · see citing works

Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma

Wang, Z., Zhang, C., Liu, X., Wang, Z., Sun, L., Li, G., Liang, J., Hu, H., Liu, Y., Zhang, W., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1196310 · Cited by 191 · see citing works

PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages

Dill, E. A., Gru, A. A., Atkins, K. A., Friedman, L. A., Moore, M. E., Bullock, T. N. J., Cross, J. V., Dillon, P. M., & Mills, A. M. (2017) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000780 · Cited by 158 · see citing works

Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer

Mansfield, A. S., Murphy, S. J., Peikert, T., Yi, E. S., Vasmatzis, G., Wigle, D. A., & Aubry, M. C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2246 · Cited by 134 · see citing works

Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma

Inoue, H., Park, J., Kiyotani, K., Zewde, M. G., Miyashita, A., Jinnin, M., Kiniwa, Y., Okuyama, R., Tanaka, R., Fujisawa, Y., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1204507 · Cited by 134 · see citing works

PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome

Obeid, J. M., Erdag, G., Smolkin, M. E., Deacon, D. H., Patterson, J. W., Chen, L., Bullock, T. N. J., & Slingluff, C. L. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1235107 · Cited by 129 · see citing works

Immunotherapy for colorectal cancer: where are we heading?

Basile, D., Garattini, S. K., Bonotto, M., Ongaro, E., Casagrande, M., Cattaneo, M., Fanotto, V., Carlo, E. D., Loupakis, F., Urbano, F., et al. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1315405 · Cited by 99 · see citing works

Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas

Inaguma, S., Lasota, J. P., Wang, Z., Felisiak-Gołąbek, A., Ikeda, H., & Miettinen, M. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.185 · Cited by 94 · see citing works

PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylation

Wang, H., Yao, H., Li, C., Liang, L., Zhang, Y., Shi, H., Zhou, C., Chen, Y., Fang, J., & Xu, J. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1327494 · Cited by 88 · see citing works

Somatic gene copy number alterations in colorectal cancer: new quest for cancer drivers and biomarkers

Wang, H., Liang, L., Fang, J.-Y., & Xu, J. (2015) · Oncogene · doi:10.1038/onc.2015.304 · Cited by 85 · see citing works

Systematic evaluation of supervised classifiers for fecal microbiota-based prediction of colorectal cancer

Ai, L., Tian, H., Chen, Z., Chen, H., Xu, J., & Fang, J. (2017) · Oncotarget · doi:10.18632/oncotarget.14488 · Cited by 78 · see citing works

Targeting the PD-1 pathway: a new hope for gastrointestinal cancers

Bi̇lgi̇n, B., Şendur, M. A. N., Akıncı, M. B., Dede, D. Ş., & Yalçın, B. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1279132 · Cited by 75 · see citing works

ArhGAP30 promotes p53 acetylation and function in colorectal cancer

Wang, J., Qian, J., Hu, Y., Kong, X., Chen, H., Shi, Q., Jiang, L., Wu, C., Zou, W., Chen, Y., et al. (2014) · Nature Communications · doi:10.1038/ncomms5735 · Cited by 69 · see citing works

Anti program death-1/anti program death-ligand 1 in digestive cancers

Guillebon, É. D. (2015) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v7.i8.95 · Cited by 53 · see citing works

An Expanding Role for Immunotherapy in Colorectal Cancer

Bever, K. M., & Le, D. T. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0037 · Cited by 49 · see citing works

Methylation levels of LINE-1 in primary lesion and matched metastatic lesions of colorectal cancer

Murata, A., Baba, Y., Watanabe, M., Shigaki, H., Miyake, K., Ishimoto, T., Iwatsuki, M., Iwagami, S., Sakamoto, Y., Miyamoto, Y., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.289 · Cited by 47 · see citing works

Fractional Genomic Alteration Detected by Array-Based Comparative Genomic Hybridization Independently Predicts Survival after Hepatic Resection for Metastatic Colorectal Cancer

Mehta, K. R., Nakao, K., Zuraek, M. B., Ruan, D. T., Bergsland, E. K., Venook, A. P., Moore, D. H., Tokuyasu, T. A., Jain, A. N., Warren, R. S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1418 · Cited by 41 · see citing works

Oridonin derivative ameliorates experimental colitis by inhibiting activated T‐cells and translocation of nuclear factor‐kappa B

Liu, Q. Q., Wang, H. L., Chen, K., Wang, S. B., Xu, Y., Ye, Q., & Sun, Y. W. (2015) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12314 · Cited by 40 · see citing works

Proteomic identification of ERP29 as a key chemoresistant factor activated by the aggregating p53 mutant Arg282Trp

Zhang, Y., Hu, Y., Wang, J.-L., Yao, H., Wang, H., Liang, L., Li, C., Shi, H., Chen, Y., Fang, J.-Y., et al. (2017) · Oncogene · doi:10.1038/onc.2017.152 · Cited by 32 · see citing works

Patients’ knowledge and fear of colorectal cancer risk in inflammatory bowel disease

Lopez, A., Collet-Fenêtrier, B., Belle, A., & Peyrin‐Biroulet, L. (2016) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12356 · Cited by 15 · see citing works

Sending family history questionnaires to patients before a colonoscopy improves genetic counseling for hereditary colorectal cancer

Kessels, K., Eisinger, J. D., Letteboer, T. G. W., Offerhaus, G. J. A., Siersema, P. D., & Moons, L. M. G. (2017) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12491 · Cited by 13 · see citing works

Colonic mucosal N‐methyl‐D‐aspartate receptor mediated visceral hypersensitivity in a mouse model of irritable bowel syndrome

Qi, Q. Q., Chen, F. X., Zhao, D. Y., Li, L. X., Wang, P., Li, Y. Q., & Zuo, X. L. (2016) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12374 · Cited by 12 · see citing works

Chinese consensus on the prevention of colorectal cancer (2016, S hanghai)

Fang, J., Yong Quan, S. H. I., Chen, Y., Li, J., & Sheng, J. Q. (2017) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12450 · Cited by 4 · see citing works

Comprehensive review of targeted therapy for colorectal cancer

Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687 · see citing works

PD-1/PD-L1 pathway: current researches in cancer.

Han, Y., Liu, D., & Li, L. (2020) · PubMed Central · Cited by 1,602 · see citing works

PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy

Dermani, F. K., Samadi, P., Rahmani, G., Kohlan, A. K., & Najafi, R. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27172 · Cited by 509 · see citing works

PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer

Yaghoubi, N., Soltani, A., Ghazvini, K., Hassanian, S. M., & Hashemy, S. I. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.105 · Cited by 303 · see citing works

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion

Wang, Y., Wang, H., Yao, H., Li, C., Fang, J., & Xu, J. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00536 · Cited by 209 · see citing works

GOLM1 exacerbates CD8+ T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages

Chen, J., Lin, Z., Liu, L., Zhang, R., Geng, Y., Fan, M.-H., Zhu, W., Lü, M., Lu, L., Jia, H., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00784-0 · Cited by 193 · see citing works

Emerging trends in colorectal cancer: Dysregulated signaling pathways (Review)

Ahmad, R., Singh, J. K., Wunnava, A., Al-Obeed, O. A., Abdulla, M., & Srivastava, S. K. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.4847 · Cited by 254 · see citing works

Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy

Yao, H., Wang, H., Li, C., Fang, J., & Xu, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01774 · Cited by 154 · see citing works

Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints

Lequeux, A., Noman, M. Z., Xiao, M., Sauvage, D., Van Moer, K., Viry, E., Bocci, I., Hasmim, M., Bosseler, M., Berchem, G., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.021 · Cited by 117 · see citing works

Molecular imaging biomarkers for immune checkpoint inhibitor therapy

van de Donk, P. P., de Ruijter, L. K., Hooge, M. N. L., Brouwers, A. H., van der Wekken, A. J., Oosting, S. F., Fehrmann, R. S. N., de Groot, D. J. A., & de Vries, E. G. E. (2020) · Theranostics · doi:10.7150/thno.38339 · Cited by 106 · see citing works

Autologous cell lines from circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy-driven tumor changes

Soler, A., Cayrefourcq, L., Mazard, T., Babayan, A., Lamy, P., Assou, S., Assénat, E., Pantel, K., & Alix‐Panabières, C. (2018) · Scientific Reports · doi:10.1038/s41598-018-34365-z · Cited by 92 · see citing works

Mechanisms of Immunosuppression in Colorectal Cancer

Zhang, Y., Rajput, A., Jin, N. Y., & Wang, J. (2020) · Cancers · doi:10.3390/cancers12123850 · Cited by 81 · see citing works

Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations

Chen, X., Chen, L., Peng, X., Deng, L., Wang, Y., Li, J.-J., Guo, D., & Niu, X. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101851 · Cited by 80 · see citing works

Extracellular Vesicles and Tumor-Immune Escape: Biological Functions and Clinical Perspectives

Raimondo, S., Pucci, M., Alessandro, R., & Fontana, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072286 · Cited by 76 · see citing works

Antitumor Effects of Ursolic Acid through Mediating the Inhibition of STAT3/PD-L1 Signaling in Non-Small Cell Lung Cancer Cells

Kang, D. Y., Sp, N., Lee, J., & Jang, K. (2021) · Biomedicines · doi:10.3390/biomedicines9030297 · Cited by 75 · see citing works

ALDH1A3 upregulation and spontaneous metastasis formation is associated with acquired chemoresistance in colorectal cancer cells

Durinikova, E., Kozovská, Z., Poturnajova, M., Plavá, J., Čierna, Z., Bábelová, A., Bohovic, R., Schmidtova, S., Tomáš, M., Kučerová, L., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4758-y · Cited by 70 · see citing works

Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1+triple negative breast cancer cells

Mohan, N., Hosain, S. B., Zhao, J. W., Shen, Y., Luo, X. L., Jiang, J., Endo, Y., & Wu, W. J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1624128 · Cited by 64 · see citing works

Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond

Bitar, S. A., El-Sabban, M. E., Doughan, S., & Abou-Kheir, W. G. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i9.1395 · Cited by 67 · see citing works

Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases

Manson, Q. F., Schrijver, W. A. M. E., ter Hoeve, N. D., Moelans, C. B., & van Diest, P. J. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9950-6 · Cited by 63 · see citing works

Biological impact and therapeutic implication of tumor-associated macrophages in hepatocellular carcinoma

Li, D., Zhang, T., Guo, Y., Bi, C., Liu, M., & Wang, G. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06888-z · Cited by 63 · see citing works

Hsa_circ_0136666 activates Treg-mediated immune escape of colorectal cancer via miR-497/PD-L1 pathway

Xu, Y., Zhao, J., Gao, C., Ni, X., Wang, W., Hu, W., & Wu, C. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110095 · Cited by 56 · see citing works

Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP)

Cheung, C. C., Barnes, P. J., Bigras, G., Boerner, S. L., BUTANY, J. W., Calabrese, F., Couture, C., Deschênes, J., El-Zimaity, H. M. T., Fischer, G., et al. (2019) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000800 · Cited by 56 · see citing works

Silibinin Regulates Tumor Progression and Tumorsphere Formation by Suppressing PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Cells

Rugamba, A., Kang, D. Y., Sp, N., Jo, E. S., Lee, J., Bae, S. W., & Jang, K. (2021) · Cells · doi:10.3390/cells10071632 · Cited by 56 · see citing works

B7-H3 immune checkpoint expression is a poor prognostic factor in colorectal carcinoma

Lu, Z., Zhao, Z., Cheng, P., Huang, F., Guan, X., Zhang, M., Chen, H., Liu, Z., Jiang, Z., Zheng, Z., et al. (2020) · Modern Pathology · doi:10.1038/s41379-020-0587-z · Cited by 49 · see citing works

Metastatic Colonization: Escaping Immune Surveillance

Schaller, J., & Agudo, J. (2020) · Cancers · doi:10.3390/cancers12113385 · Cited by 50 · see citing works

The Interplay of Autophagy and Tumor Microenvironment in Colorectal Cancer—Ways of Enhancing Immunotherapy Action

Koustas, E., Sarantis, P., Kyriakopoulou, G., Papavassiliou, A. G., & Karamouzis, M. V. (2019) · Cancers · doi:10.3390/cancers11040533 · Cited by 49 · see citing works

High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer

Engerud, H., Berg, H. F., Myrvold, M., Halle, M. K., Bjørge, L., Haldorsen, I. S., Høivik, E. A., Trovik, J., & Krakstad, C. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.01.020 · Cited by 49 · see citing works

Mechanistic Insights of Anti-Immune Evasion by Nobiletin through Regulating miR-197/STAT3/PD-L1 Signaling in Non-Small Cell Lung Cancer (NSCLC) Cells

Sp, N., Kang, D. Y., Lee, J., & Jang, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189843 · Cited by 46 · see citing works

Polydatin Exerts an Antitumor Effect Through Regulating the miR-382/PD-L1 Axis in Colorectal Cancer

Jin, Y., Zhan, X., Zhang, B., Chen, Y., Liu, C., & Yu, L. (2019) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2019.2999 · Cited by 45 · see citing works

Comparison of Mismatch Repair Status Between Primary and Matched Metastatic Sites in Patients With Colorectal Cancer

He, W., Hu, W.-M., Wang, F., Rong, Y.-M., Yang, L., Xie, Q.-K., Yang, Y., Jiang, C., Qiu, H., Lu, J.-B., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.7308 · Cited by 44 · see citing works

PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer

Wei, X., Luo, X., Sheng, H., Wang, Y., Chen, D., Li, J.-N., Wang, F., & Xu, R. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02636-x · Cited by 43 · see citing works

Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy

Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A. (2024) · Cancers · doi:10.3390/cancers16111995 · Cited by 37 · see citing works

Targeted Therapies in Colorectal Cancer: Recent Advances in Biomarkers, Landmark Trials, and Future Perspectives

Manzi, J. L. L., Hoff, C. O., Ferreira, R., Pimentel, A., Datta, J., Livingstone, A. S., Vianna, R., & Abreu, P. (2023) · Cancers · doi:10.3390/cancers15113023 · Cited by 40 · see citing works

THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy

Li, C., Chi, H., Deng, S., Xu, K., Wang, H., Yao, H., Wang, Y., Chen, D., Guo, X., Fang, J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002443 · Cited by 37 · see citing works

Predictors of response to immunotherapy in colorectal cancer

González‐Montero, J., Rojas, C. I., & Burotto, M. (2024) · The Oncologist · doi:10.1093/oncolo/oyae152 · Cited by 34 · see citing works

Pharmacogenomics, biomarker network, and allele frequencies in colorectal cancer

López‐Cortés, A., Paz‐y‐Miño, C., Guerrero, S. X., Jaramillo-Koupermann, G., Cáceres, Á. L., Intriago-Baldeón, D. P., Garcí­a-Cárdenas, J. M., Guevara‐Ramírez, P., Armendáriz‐Castillo, I., Leone, P., et al. (2019) · The Pharmacogenomics Journal · doi:10.1038/s41397-019-0102-4 · Cited by 29 · see citing works

Cross-Talk Between Tumor Cells Undergoing Epithelial to Mesenchymal Transition and Natural Killer Cells in Tumor Microenvironment in Colorectal Cancer

Vuletić, A. M., Martinović, K. M., Miletić, N. T., Zoidakis, J., Castellvı́-Bel, S., & Cavic, M. R. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.750022 · Cited by 26 · see citing works

Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer

Alkholifi, F. K., & Alsaffar, R. M. (2022) · Medicina · doi:10.3390/medicina58111572 · Cited by 28 · see citing works

Unveiling the immune symphony: decoding colorectal cancer metastasis through immune interactions

He, R., Huang, S., Lu, J., Su, L., Gao, X., & Chi, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1362709 · Cited by 29 · see citing works

Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer (CRC)

Pang, S.-W., Awi, N. J., Armon, S., Lim, W. W.-D., Low, J. S.-H., Peh, K.-B., Peh, S., & Teow, S. (2019) · Diagnostics · doi:10.3390/diagnostics10010009 · Cited by 26 · see citing works

Expanding the Potential of Circular RNA (CircRNA) Vaccines: A Promising Therapeutic Approach

Bu, T., Yang, W., Zhao, J., Gao, Y., Li, F., & Yang, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26010379 · Cited by 30 · see citing works

MicroRNA‑519 inhibits hypoxia‑induced tumorigenesis of pancreatic cancer by regulating immune checkpoint PD‑L1

Nong, K., Zhang, D., Chen, C., Yang, Y., Yong, Y., Liu, S., & Cai, H. (2019) · Oncology Letters · doi:10.3892/ol.2019.11234 · Cited by 26 · see citing works

Anticipating metastasis through electrochemical immunosensing of tumor hypoxia biomarkers

Martín, C. M., Gamella, M., Pedrero, M., Montero‐Calle, A., Pérez‐Ginés, V., Camps, J., Arenas, M., Barderas, R., Pingarrón, J. M., & Campuzano, S. (2021) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-021-03240-8 · Cited by 26 · see citing works

Retrospective analysis of the prognostic value of PD-L1 expression and 18F-FDG PET/CT metabolic parameters in colorectal cancer

Jiang, H., Zhang, R., Jiang, H., Zhang, M., Guo, W., Zhang, J., Zhou, X., Pan, W., Zhao, S., & Li, P. (2020) · Journal of Cancer · doi:10.7150/jca.38689 · Cited by 24 · see citing works

Role of Histone Deacetylase 6 and Histone Deacetylase 6 Inhibition in Colorectal Cancer

Vuletić, A. M., Martinović, K. M., & Spasić, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010054 · Cited by 24 · see citing works

Expression of PD-L1 in primary breast carcinoma and lymph node metastases

Alves, A. M. D. S., Paredes, J., & Schmitt, F. C. (2019) · Surgical and Experimental Pathology · doi:10.1186/s42047-019-0033-z · Cited by 21 · see citing works

Forces at play: exploring factors affecting the cancer metastasis

Riaz, F., Zhang, J., & Pan, F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1274474 · Cited by 20 · see citing works

PD-L1 importance in malignancies comprehensive insights into the role of PD-L1 in malignancies: from molecular mechanisms to therapeutic opportunities

Soltani, M., Abbaszadeh, M., Fouladseresht, H., Sullman, M. J. M., & Eskandari, N. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01641-y · Cited by 18 · see citing works

Nanomaterial Manipulation of Immune Microenvironment in the Diseased Liver

Hu, M., & Huang, L. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201805760 · Cited by 17 · see citing works

The role of the immunoescape in colorectal cancer liver metastasis

Takasu, C., Yamashita, S., Morine, Y., Yoshikawa, K., Tokunaga, T., Nishi, M., Kashihara, H., Yoshimoto, T., & Shimada, M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259940 · Cited by 15 · see citing works

The clinical significance of PD‑L1 in colorectal cancer (Review)

Ntomi, V., Foukas, P. G., Papaconstantinou, D., Antonopoulou, I., Pikoulis, A., Panagiotides, I., Pikoulis, E. A., & Syrigos, K. (2021) · Oncology Reports · doi:10.3892/or.2021.8043 · Cited by 14 · see citing works

High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer

Möller, K., Blessin, N. C., Höflmayer, D., Büscheck, F., Luebke, A. M., Kluth, M., Hube‐Magg, C., Zalewski, K., Hinsch, A., Neipp, M., et al. (2021) · Acta Oncologica · doi:10.1080/0284186x.2021.1933585 · Cited by 14 · see citing works

Comparisons of metastatic patterns of colorectal cancer among patients by age group: a population-based study

Yang, L., Yang, X., He, W., Liu, S., Jiang, C., xie, K., Peng, K., You, Y., Zhang, B., & Xia, L. (2018) · Aging · doi:10.18632/aging.101700 · Cited by 14 · see citing works

Case report: The MSI-L/p-MMR metastatic rectal cancer patient who failed systemic therapy responds to anti-PD-1 immunotherapy after stereotactic body radiation-therapy

Liu, S., Zhang, Y., Lin, Y., Wang, P., & Pan, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.981527 · Cited by 13 · see citing works

Heterogeneity of PD-L1 expression and CD8 lymphocyte infiltration in metastatic colorectal cancer and their prognostic significance

Xin, H., Zhou, C., Wang, G., Liu, Y., Zhang, J., Liu, Y., Li, B., Zhang, J., Su, M., Li, Z., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13048 · Cited by 13 · see citing works

Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy

Huemer, F., Klieser, E., Neureiter, D., Schlintl, V., Rinnerthaler, G., Pagès, F., Kirilovsky, A., Sissy, C. E., Iglseder, W., Singhartinger, F. X., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092775 · Cited by 13 · see citing works

Isolation and Characterization of Two Novel Colorectal Cancer Cell Lines, Containing a Subpopulation with Potential Stem-Like Properties: Treatment Options by MYC/NMYC Inhibition

Esch, J. S. A., Windmöller, B. A., Hanewinkel, J., Storm, J., Förster, C., Wilkens, L., Krüger, M., Kaltschmidt, B., & Kaltschmidt, C. (2020) · Cancers · doi:10.3390/cancers12092582 · Cited by 12 · see citing works

Immunohistochemistry as predictive and prognostic markers for gastrointestinal malignancies

Rosenbaum, M. W., & González, R. S. (2021) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2021.10.003 · Cited by 11 · see citing works

Frequency of discordance in programmed death-ligand 1 (PD-L1) expression between primary tumors and paired distant metastases in advanced cancers: a systematic review and meta-analysis

Lee, C. C., Soon, Y. Y., Lum, H. Y. J., Tan, C. L., & Tey, J. C. S. (2020) · Acta Oncologica · doi:10.1080/0284186x.2020.1741678 · Cited by 11 · see citing works

Heteronemin and Tetrac Induce Anti-Proliferation by Blocking EGFR-Mediated Signaling in Colorectal Cancer Cells

Unson, S., Chang, T., Yang, Y., Wang, S., Huang, C., Crawford, D. R., Huang, H., Li, Z., Lin, H., Whang‐Peng, J., et al. (2022) · Marine Drugs · doi:10.3390/md20080482 · Cited by 11 · see citing works

Cancer invasion and metastasis: Insights from murine pubertal mammary gland morphogenesis

Githaka, J. M., Pirayeshfard, L., & Goping, I. S. (2023) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2023.130375 · Cited by 11 · see citing works

Molecular Subtypes, microRNAs and Immunotherapy Response in Metastatic Colorectal Cancer

Gherman, A., Bolunduț, D., Ecea, R., Bălăcescu, L., Curcean, S., Dina, C., Bălăcescu, O., & Cainap, C. I. (2024) · Medicina · doi:10.3390/medicina60030397 · Cited by 10 · see citing works

Hydroxyproline metabolism enhances IFN-γ-induced PD-L1 expression and inhibits autophagic flux

Spangenberg, S. H., Palermo, A., Gazaniga, N. R., Martínez‐Peña, F., Guijas, C., Chin, E. N., Rinschen, M. M., Sander, P. N., Webb, B., Pereira, L. E., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.06.016 · Cited by 9 · see citing works

Immunotherapy against colorectal cancer via delivery of anti-PD-L1 nanobody mRNA

Chu, W., Ma, L., Hew, B. E., Sugawara, A., Wengrill, R., Guarary, A., Irei, J. S., Chan, O. T. M., Wang, J., Muramtsu, H., et al. (2025) · eGastroenterology · doi:10.1136/egastro-2024-100106 · Cited by 7 · see citing works

Spatiotemporal Changes in Checkpoint Molecule Expression

Li, W., Qie, J., Zhang, Y., & Chang, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_8 · Cited by 7 · see citing works

Impact of PD‑L1 upregulation on immune checkpoint inhibitor efficacy in triple‑negative breast cancer using a 4T1 murine model

Park, A., Kim, J. H., Lee, S. E., Kim, H., Kim, H., Lee, H., & Han, W. (2025) · International Journal of Oncology · doi:10.3892/ijo.2025.5760 · Cited by 5 · see citing works

Unlocking the potential of novel tetrahydro-β-carboline-based HDAC6 inhibitors for colorectal cancer therapy: Design, synthesis and biological evaluation

Hemida, N., El‐Gamil, D. S., ElHady, A. K., Lin, K.-C., Chang, Y.-H., Hilscher, S., Schutkowski, M., Ibrahim, H. S., Hamed, M. M., Chen, S., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108454 · Cited by 5 · see citing works

Therapeutic Potential of Mitotic Kinases’ Inhibitors in Cancers of the Gastrointestinal System

Javed, A., Malagraba, G., Yarmohammadi, M., Perelló-Reus, C. M., Barceló, C., & Rubio‐Tomás, T. (2022) · Future Pharmacology · doi:10.3390/futurepharmacol2030015 · Cited by 5 · see citing works

New Potential Immune Biomarkers in the Era of Precision Medicine: Lights and Shadows in Colorectal Cancer

Damato, A., Rotolo, M., Caputo, F., Borghi, E., Iachetta, F., & Pinto, C. (2022) · Life · doi:10.3390/life12081137 · Cited by 5 · see citing works

CD3+ and CD8+ T-Cell-Based Immune Cell Score and PD-(L)1 Expression in Pulmonary Metastases of Microsatellite Stable Colorectal Cancer

Karjula, T., Elomaa, H., Niskakangas, A., Mustonen, O., Puro, I., Kuopio, T., Ahtiainen, M., Mecklin, J., Seppälä, T. T., Wirta, E., et al. (2022) · Cancers · doi:10.3390/cancers15010206 · Cited by 5 · see citing works

Baicalein Enhances Radiosensitivity in Colorectal Cancer via JAK2 / STAT3 Pathway Inhibition

Yu, Q., Tang, R., Mo, W., Zhao, L., & Li, L.-D. (2024) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14611 · Cited by 5 · see citing works

The Potential Dual Role of H2.0-like Homeobox in the Tumorgenesis and Development of Colorectal Cancer and Its Prognostic Value

Chen, S., Zhang, L., Wang, K., Huo, J., Zhang, S., & Zhang, X. (2023) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2023/5521544 · Cited by 4 · see citing works

PD-L1 Expression in Paired Samples of Rectal Cancer

Coussement, M., Fazio, R., Audisio, A., Khoury, R. E., Abbassi, F.-Z., Assaf, I., Conti, C., Gallio, C., Benhima, N., Bregni, G., et al. (2024) · Cancers · doi:10.3390/cancers16142606 · Cited by 3 · see citing works

Quinidine dosage in children using population estimates.

Burckart, G. J., & Marı́n-Garcı́a, J. (1986) · PubMed · Cited by 3 · see citing works

Study of the PD-L1 status in breast cancer, by using the SP142 monoclonal antibody, and the prospects for determining treatment policy

Франк, Г. А., Кузнецова, О. А., Эдуардовна, З. Л., Andreeva, Y. Y., & Moskvina, L. V. (2019) · Russian Journal of Archive of Pathology · doi:10.17116/patol2019810515 · Cited by 3 · see citing works

Targeting oncogenic signaling pathways in lung Cancer: The emerging role of nobiletin, a flavonoid from citrus peel

Suwal, N., Thapa, R., Bashyal, S., Sugandhi, V. V., Subedi, S., Panth, N., Amorim, N. M. L., Choi, J. P., Gupta, M., Idrees, S., et al. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.106887 · Cited by 2 · see citing works

Organotropic metastasis in colorectal cancer: integrating molecular pathways with therapeutic opportunities

He, J. N., Gao, Y., Sun, Z. S., Li, Y., Wang, J., Zhang, L., & Liu, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1686071 · Cited by 2 · see citing works

Expresion paterns of various PDCD1 and PDL1 isoforms in prostate tumors

Gerashchenko, G. V., Kononenko, O. A., Bondarenko, Y. M., Stakhovsky, E. O., Tkachuk, Z. Y., Tukalo, M. A., & Kashuba, V. I. (2022) · Biopolymers and Cell · doi:10.7124/bc.000a7c · Cited by 2 · see citing works

Immunohistochemical Expression of Programmed Death Ligand- 1 (PD-L1) in Colorectal Carcinoma; A Cross-sectional Study

Tadachina, S., Shivalingaiah, S. D. C., & Shetty, M. (2024) · Iranian journal of pathology · doi:10.30699/ijp.2023.1988660.3054 · Cited by 2 · see citing works

Exploring the potential biological function of GRK2 in colorectal cancer

Gao, M., Liang, X., Fan, M., Wu, Y., Dong, M., & Du, R. (2024) · Functional & Integrative Genomics · doi:10.1007/s10142-024-01322-1 · Cited by 1 · see citing works

Pan‐cancer evaluation of tumor‐infiltrating lymphocytes and programmed cell death protein ligand‐1 in metastatic biopsies and matched primary tumors

Beaino, Z. E., Dupain, C., Marret, G., Paolettí, X., Fuhrmann, L., Martinat, C., Allory, Y., Halladjian, M., Bièche, I., Tourneau, C. L., et al. (2024) · The Journal of Pathology · doi:10.1002/path.6334 · Cited by 1 · see citing works

Phase 1b Multicenter Study of SG001, a Humanized Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors

Fang, J., Jiang, O., Li, W., Lin, J., Fang, M., Li, Q., Zhao, W., Wang, K., Shi, H., Chen, Z., et al. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s546663 · Cited by 1 · see citing works

Immune architecture of colorectal cancer brain metastases: spatial TAM heterogeneity and PD-L1 dynamics

Grape, L. M., Hanke, B., Neyazi, B., Rashidi, A., Swiatek, V. M., Schaufler, A., Dumitru, C. A., Kahlert, U. D., Croner, R. S., Mawrin, C., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1816086 · Cited by 1 · see citing works

Impact of cancer immunotherapies on oocyte health and ovarian function

Lewis, Y., Cao, Y., Higgins, J., Alesi, L. R., Winship, A., & Hutt, K. J. (2026) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2026.04.006 · Cited by 1 · see citing works

Correlation between PD-L1 Expression, Clinicopathological Factors, and Metastasis Risk in Colorectal Cancer Patients

Zarbakhsh, A., Khalaji, A., Vahedi, A., Dolatkhah, R., & Gholami, N. (2024) · European Journal of Cancer Care · doi:10.1155/2024/5578953 · Cited by 1 · see citing works

Current drug therapy for colorectal cancer

Mohapatra, L., Tripathi, A. S., Alka, Mishra, D. K., Parida, S. K., Yasir, M., Maurya, R. K., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13870-6.00014-3 · Cited by 1 · see citing works

Recent Advancements in the Inhibition of Metastasis of Colorectal Cancer Using Anticancer Compounds

Chhetri, D., Ilango, K., Palaniyandi, K., & Gnanasampanthapandian, D. (2024) · Springer eBooks · doi:10.1007/978-981-99-6263-1_48 · Cited by 1 · see citing works

Upregulation of LncRNAs G2E3-AS1 and BACE1-AS as prognostic biomarkers in metastatic colorectal cancer

kenari, S. N., Mohamadynejad, P., Moghanibashi, M., Bagheri, A., & Rouhi, L. (2025) · Biomarkers · doi:10.1080/1354750x.2024.2448508 · Cited by 1 · see citing works

Molecular biomarkers in current management of metastatic colorectal cancer

Tanasanvimon, S. (2018) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2018.38 · Cited by 1 · see citing works

Prognostic value of tumor immune biomarkers in biopsies from patients with refractory solid cancers

Lambert, T., Pobel, C., Daage, L. C., Bigorgne, A., RaubyY, B., Aladro, N. S.-E., Ter-MinassianN, L., Kerisit, M., Marabelle, A., Besse, B., et al. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100611

Recent Advancements in the Inhibition of Metastasis of Colorectal Cancer Using Anticancer Compounds

Chhetri, D., Ilango, K., Palaniyandi, K., & Gnanasampanthapandian, D. (2023) · Springer eBooks · doi:10.1007/978-981-99-2196-6_48-1

IMMUNOHISTOCHEMICAL EXPRESSION OF PROGRAMMED DEATH-LIGAND 1 (PDL-1) IN COLORECTAL ADENOCARCINOMA AT H. ADAM MALIK GENERAL HOSPITAL MEDAN

Ramadansyah, Alferraly, T. I., Chrestella, J., Delyuzar, & Laksmi, L. I. (2023) · International Journal of Research Publications · doi:10.47119/ijrp10013611120235637

Clinical insights into the efficacy of immune checkpoint inhibitors in patients with cancer

de Ruijter, L. K. (2024) · doi:10.33612/diss.952617592

Cancer signaling pathways: targets and treatment

Vishnusai, B., Sharma, R., Parihar, V. K., & Kumar, N. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95258-3.00006-0

Acute Hemorrhagic Rectal Ulcer in a Uremic Patient: A Case Report and Literature Review

Liu, D., Han, X., Li, M., Li, L., Huang, Y., & Song, J. (2025) · Hemodialysis International · doi:10.1111/hdi.13273

Additional file 1 of PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer

Wei, X.-L., Luo, X., Sheng, H., Wang, Y., Chen, D.-L., Li, J.-N., Wang, F.-H., & Xu, R.-H. (2020) · Figshare · doi:10.6084/m9.figshare.13468261

Caractérisations phénotypiques et moléculaires de lignées cellulaires issues de cellules tumorales circulantes dans le cancer du colon

Soler, A. (2018) · doi:10.70675/ca3e4f2fzc605z4417zbbc7zee885588cc9a

Impact du ciblage du domaine de liaison de HIF-1α avec HIF-1β sur le paysage immunitaire du mélanome

Lequeux, A. (2020) · theses.fr (ABES) · doi:10.70675/a29d12dbz79c1z4d37za978z2e2319131c82

Determinants of Colorectal Cancer: An Integrative Immunometabolic Framework Linking Biomarkers, Therapy, and the Diet–Microbiota Axis

Aguiari, G., Bianchi, N., & Franzese, O. (2026) · Cells · doi:10.3390/cells15121074

Transition of the programmed death 1 pathway from the primary colorectal cancer to its corresponding pulmonary metastasis

Miyamoto, E., Chen-Yoshikawa, T. F., Ueshima, C., Yoshizawa, A., Hamaji, M., Yamamoto, T. S., Kawada, K., Haga, H., Sakai, Y., & Date, H. (2018) · Journal of Surgical Oncology · doi:10.1002/jso.25045 · Cited by 4 · see citing works

Correlation of pd-l1 staining in tumor cells and tumor infiltrate between primary tumors and matched metastasis in advanced colorectal cancer patients

Tampellini, M., Falco, E. C., Rosa, G. D., Montarolo, F., Dacomo, R., Baratelli, C., Sperti, E., Maïo, M. D., Giorgio, V. S., & Volante, M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx263.026

Characteristics of expressions of programmed death receptor 1 and its ligand in colorectal metastases

Zu, F., & Wang, Y. (2019) · doi:10.3760/cma.j.issn.1006-9801.2019.04.015

Heterogeneity of PD-L1 expression and CD8 lymphocyte infiltration in metastatic colorectal cancer and their prognostic significance

Xin, H., Zhou, C., Wang, G., Liu, Y., Zhang, J., Liu, Y., Li, B., Zhang, J., Su, M., Li, Z., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13048 · Cited by 13 · see citing works

PD-L1 expression in metastatic colorectal carcinoma

Krsteska, B., Filipovski, V. A., Sabit, K. K., Jasar, D., Todorovska, M. B., & Velickova, N. (2024) · Goce Delchev University Repository (Goce Delčev University of Štip)